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During infection, humoral immunity produces a
polyclonal response with various immunoglobulins
recognizing different epitopes within the microbe or
toxin. Despite this diverse response, the biological
activity of an antibody (Ab) is usually assessed by
the action of a monoclonal population. We demon-
strate that a combination of monoclonal antibodies
(mAbs) that are individually disease enhancing or
neutralizing to Bacillus anthracis protective antigen
(PA), a component of anthrax toxin, results in signif-
icantly augmented protection against the toxin.
This boosted protection is Fc gamma receptor
(FcgR) dependent and involves the formation of
stoichiometrically defined mAb-PA complexes that
requires immunoglobulin bivalence and simulta-
neous interaction between PA and the two mAbs.
The formation of these mAb-PA complexes inhibits
PA oligomerization, resulting in protection. These
data suggest that functional assessments of single
Abs may inaccurately predict how the same Abs
will operate in polyclonal preparations and imply
that potentially therapeutic mAbsmay be overlooked
in single Ab screens.
INTRODUCTION
Antibody-mediated immunity (AMI) is crucial for combating
diseases. Hybridoma technology produces individual Abs as
monoclonal preparations, which allows the study of single immu-
noglobulins (Ko¨hler and Milstein, 1975). Consequently, most
studies of mAb efficacy evaluate single preparations and classify
the immunoglobulins as protective, indifferent, or disease-
enhancing depending on how they modify the course of infec-
tion, cancer progression, or toxemia (Mukherjee et al., 1992;
Pethe et al., 2001; Abboud et al., 2010; Scheid et al., 2011).
Several neutralizing mAbs have been developed as therapeutics
(Saylor et al., 2009), and in particular, they are promising candi-
dates to treat toxin-mediated infectious diseases (Migone et al.,
2009; Lowy et al., 2010). The major effort in mAb discovery and
characterization has been focused on candidates with therapeu-Cell Htic potential, but a paradox of AMI is that most antitoxin Abs are
nonprotective (Chow and Casadevall, 2012). Disease-enhancing
mAbs have been reported pertaining to toxins (Maddaloni et al.,
2004), bacteria (Mohamed et al., 2004; Little et al., 2011), and
viruses (Peiris and Porterfield, 1979; Takeda et al., 1988; Dejnir-
attisai et al., 2010). In contrast to their protective counterparts,
relatively few enhancing mAbs have been studied in detail, and
there is no good explanation of why such Abs are generated in
an immune response or how they affect the host.
Various papers report that the potency of protective mAbs can
be augmented additively or synergistically by the addition of
other protective mAbs. The mixing of protective mAbs targeting
different epitopes of a toxin molecule can synergize protective
efficacy (Cheng et al., 2009; Demarest et al., 2010; Varshney
et al., 2011; Ngundi et al., 2012). Combining neutralizing mAbs
to individual toxin components boosts protection against toxicity
(Brossier et al., 2004; Chen et al., 2009). The primary rationale
for mixing multiple protective mAbs is to achieve additivity or
synergy by targeting different epitopes of the virulence factors
and reducing the potential for selecting escape variants (Logten-
berg, 2007), while the combinational approaches also have the
potential to approximate the complexity of natural AMI. In
contrast, enhancing Abs have been rarely studied in polyclonal
preparations or in combination with other mAbs.
The system that involves the combination of protective antigen
(PA) and lethal factor (LF) to form lethal toxin (LeTx) allows mAb
toxin neutralizing efficacy to be easily measured in vitro and
in vivo (Little et al., 1988; Rivera et al., 2006; Abboud et al.,
2010). The macrophage cytotoxicity assay allows the assess-
ment of Ab protection against the cytotoxic effects of LeTx
in vitro (Welkos et al., 1986), and these results are often translat-
able to in vivo studies (Brossier et al., 2004; Rivera et al., 2006;
Abboud et al., 2010). Here we report that mAbs that are disease
enhancing when evaluated individually can boost the efficacy of
protective mAbs against LeTx.
RESULTS
Generation of PA-Specific Protective, Enhancing,
and Indifferent mAbs
Splenocytes from a BALB/c mouse immunized with GalXM-PA
vaccine (Chow and Casadevall, 2011) were fused with myeloma
fusion partner to generate hybridoma cells. Twenty hybridomas
that secreted PA (PA83)-binding mAbs were isolated and stabi-
lized by cloning twice in soft agar. We sequenced the mRNAost & Microbe 13, 417–428, April 17, 2013 ª2013 Elsevier Inc. 417
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Figure 1. Protective and Disease-Enhancing Activities of PA-
Specific mAbs
(A) The protective efficacy of individual mAbs was measured by MTT assay
with J774.16 cells. The viabilities of cells treated with media or LeTx only were
used as references to determine mAbs to be protective (green), indifferent
(black), or enhancing (red). The inset is the magnification of the region showing
only indifferent (black) and enhancing (red) mAbs.
(B and C) The effect of protective mAbN2D6 (green) and enhancing mAb N1F7
(red) on LeTx toxicity studied by MTT assay using J774.16 macrophage-like
cells, with (B) PA concentration being constant (0.5 mg/ml) and the one of LF
titrated, and (C) LF concentration being constant (0.5 mg/ml) and the one of PA
titrated vice versa. mAb concentration, 5 mg/ml. Error bars, mean ± SD;
***p < 0.0005, **p < 0.005, *p < 0.05 protective mAb versus no mAb; ###p <
0.0005, ##p < 0.005, #p < 0.05 enhancing mAb versus no mAb, all by t test.
(D) Dose-dependent survival of BALB/c mice challenged with LeTx (35 mg of
PA and LF each) 4 hr after preinjection of protective mAb N2D6 or enhancing
mAbN1F7. PBS control was used as reference. Data shown are representative
of three independent experiments.Means and SD of triplicates are shown from
one representative experiment out of three (A–C). In vivo studies are repre-
sentative of two independent experiments with n = 5 mice per group; **p <
0.005, *p < 0.05 log-rank test. See also Figure S1 and Table S1.
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418 Cell Host & Microbe 13, 417–428, April 17, 2013 ª2013 Elseviercoding for the variable region of the heavy and light chains to
confirm that the hybridomas were unique and not clonally iden-
tical. The isotype distribution was 3 IgG2a and 17 IgG1. We then
studied the binding domain of the PAmolecule recognized by the
mAbs bywestern blotting, with the tested targets being PA83, the
pre-furin-cleaved form of PA, and the fragments PA63 and PA20
generated by the cleavage (see Table S1 online). The mAbs
were then characterized individually for their capacity to
neutralize LeTx using MTT assays with J774.16 macrophage-
like cells. Depending on their toxin-neutralizing activity we cate-
gorized these mAbs as protective (10%), enhancing (30%), and
indifferent (60%) and observed that mAbs with similar activity
to the toxin shared higher similarity in their sequences (Table
S1). Protective mAbs reduced LeTx toxicity while enhancing
mAbs augmented it (Figure 1A), and indifferent mAbs had no
effect. These data are consistent with our prior finding that pro-
tective mAbs are the minority among reported mAbs (Chow and
Casadevall, 2012).
To examine the cytotoxic effect of LeTx in a concentration-
dependent manner in the presence of a constant amount of
protective or enhancing mAb, J774.16 macrophages were
treated with various concentrations of PA and LF (Figures 1B
and 1C). The results revealed a 10-fold difference in the LeTx
amount needed to kill the macrophages between the protective
mAb- and enhancing mAb-treated conditions. To determine
whether mAbs N2D6 and N1F7 mediated protection or disease
enhancement in vivo, we challenged BALB/c mice with LeTx
after injection of PBS control or individual mAbs (Figure 1D).
N2D6 prolonged the survival of treated mice, while N1F7 pro-
duced disease enhancement as manifested by reduced survival
in a dose-dependent manner. The mice treated with 1 mg of
N1F7 became very sick 30 hr prior to the PBS control group,
even though the disease enhancement was not entirely reflected
by the survival curve.
Combination of Protective and Enhancing mAbs to PA
Boosted Protection against LeTx
Given the complexity of AMI and its polyclonal nature, we
attempted to examine our 20 PA-specific mAbs in combinations
of twomAbs at one time, mimicking a controlled polyclonal envi-
ronment, and measured whether the combination exhibited any
changes in protective efficacy against LeTx. Indifferent mAbs
did not gain protective efficacy upon mixing (Figure S1). Unex-
pectedly, five of six disease-enhancing mAbs manifested
augmented protective efficacy against LeTx when combined
with a protective mAb (Figures 2A–2C). This phenomenon was
not specific to one individual mAb-mAb pair, as similar results
were observed with five enhancing mAbs and three protective
mAbs in our library (Figures 2A–2C). Of these mAbs, protective
mAb 19D9 was previously described (Abboud et al., 2009,
2010). Protective mAb N2D6 and enhancing mAb N1F7 were
selected for further study since they shared the same isotype
as IgG2a and had comparable dissociation constants (Kds)
(3.923 108 M and 1.873 108 M, respectively). We then stud-
ied the efficacy of protectivemAb against LeTx in the presence of
constant amount of enhancing mAb, and observed that protec-
tive mAbs exhibited about 100-fold more toxin-neutralizing
capacity and that an indifferent mAb became slightly protective
(Figure 2D). The results obtained with the MTT assay (Figure 2E,Inc.
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Figure 2. Combination of Protective and Enhancing mAbs to PA Boosts Protection against LeTx
(A–D) The protective efficacy of enhancing mAbs (red) in the presence of protective mAbs (green), (A) N2D6, (B) N5C10, (C) 19D9, respectively, measured byMTT
assay, with the concentration of protective mAbs being constant (1 mg/ml). (D) The protective efficacy of protective mAbs (green) and indifferent mAb (black) was
determined by MTT assay in the absence (dotted line) and presence (solid line) of enhancing mAb, N1F7 (red), with the concentration of N1F7 being constant
(0.1 mg/ml). mAb 19D9 was described by Abboud et al. (2010). Error bars, mean ± SD; ***p < 0.0005 absence of N1F7 versus corresponding presence of N1F7
counterparts, by t test.
(E) LDHmeasurementmirrored results from theMTT assay to show significant protection against LeTx by combining protective and enhancingmAbs. (Top panel)
MTT assay showed the protective efficacy against LeTx of protective mAb (green), enhancing mAb (red), and their mixture (black). (Bottom panel) LDH
measurement showed the same protection pattern as MTT assay.
(F) Percentage survival of BALB/cmice challengedwith LeTx (35 mg of PA and LF each) 4 hr after preinjection of PBS, individual mAb (N2D6 as protective, N1F7 as
enhancing), or mAbmixture (1mgmAb each per mouse). The irrelevant mAbwas 18B7, an IgG1murinemAb that did not bind to PA or LF (Mukherjee et al., 1992).
In vivo studies are representative of two independent experiments with n = 5mice per group; **p < 0.005, *p < 0.05 log rank test. Data shown are representative of
two independent experiments. Means and SD of triplicates are shown from one representative experiment out of two (A–E).
Cell Host & Microbe
Deleterious Antibodies Can Be Beneficialtop) were confirmed using lactate dehydrogenase (LDH) release
as an independent measure of cytotoxicity (Figure 2E, bottom).
To determine whether the mixing of protective and enhancing
mAbs augmented protection in vivo, we preinjected BALB/c
mice with PBS, individual mAb (N2D6 as protective, N1F7 as
enhancing, irrelevant IgG1 mAb), or mAb mixture followed by
the challenge of LeTx (Figure 2F). The specific inoculum of
LeTx was chosen since it is the minimum dosage that can result
in 100% mortality in BALB/c mice (Moayeri and Leppla, 2009).
The dosage of protective mAb was chosen based on a previous
protection study against B. anthracis in a murine model (Winter-
roth et al., 2010). Equal amounts of enhancing mAb were used to
fulfill the condition of 1:1 molar ratio between the mAb pairs
based on the peakprotection observed in theMTTassay (Figures
2A–2C). With this experimental design the concentration of
enhancing mAb was not optimized to kill the mice, but evidence
for disease enhancement was observed as the mice treated withCell Henhancing mAb became very sick 30 hr prior to the PBS-treated
mice. The mice treated with enhancing mAb without LeTx were
used as negative control, indicating that the enhanced toxicity
was accounted by the interaction between the toxin and
enhancing mAb. The administration of protective mAb alone
and in combination with irrelevant mAb significantly prolonged
the survival of mice compared to the control, while no difference
in protection was found between the two. Remarkably, all mice
injected with the protective and enhancing mAb combination
survived LeTx challenge. These results indicate that the combi-
nation of protective and enhancing mAbs resulted in synergistic
protection that relied on the molar ratio of the two mAbs.
Competition for Binding PA Molecule Abrogates
Synergistic Protection by mAb Combination
The fact that the combination of multiple protective mAbs
competing for epitopes diminishes the overall protective efficacyost & Microbe 13, 417–428, April 17, 2013 ª2013 Elsevier Inc. 419
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Figure 3. Epitope Competition of the Protective and Enhancing mAbs Results in No Synergistic Protection
Competition binding assay for PA between protective mAbs (green) and enhancing mAbs (red) as determined using inhibition ELISA. The concentration of
protectivemAbs (A) N2D6, (B) N5C10, and (C) 19D9, respectively, was kept constant (2 mg/ml), and those of enhancingmAbswere titrated, and vice versa. (D) The
protective efficacy of whole IgG mAbs compared with their Fab fragments by MTT assay. The concentration of N2D6 whole IgG and Fab is 6.67 nM. Data shown
are representative of three independent experiments. Means and SD of triplicates are shown from one representative experiment out of three (A–D).
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multiple mAbs and the antigen on protective synergy (Henchal
et al., 1988). One of the enhancingmAbs, N5D7, did not augment
protection against LeTx upon mixing with a protective mAb
(Figures 2A–2C). To determine whether the lack of protection in
the N5D7 combination was caused by competition between
the two mAbs, we performed a competition study by ELISA.420 Cell Host & Microbe 13, 417–428, April 17, 2013 ª2013 ElsevierNo competition was observed for all mAb combinations
except those involving N5D7, indicating different specificities
(Figures 3A–3C). A difference in epitope specificity was a neces-
sary but not sufficient condition for synergy in toxin neutraliza-
tion, since the mixing of one mAb with its Fab counterpart did
not confer augmented protection against LeTx (Figure 3D).
Hence, removal of Fc region and bivalence by papain digestionInc.
Figure 4. Immunoglobulin Bivalence and FcgR Engagement Contribute to Protective Synergy
(A) The function of Fc region in Ab-mediated protection wasmeasured by comparing LeTx cytotoxicity on bonemarrowmacrophages (BMMs) derived from FcRg
chain/FcgRII double knockout (FcRg//RIIB/) and wild-type (WT) mice using MTT assay. Error bars, mean ± SD; **p < 0.005, *p < 0.05 WT BMM N2D6 with
N1F7whole IgG versus with N1F7Fab;
&&p < 0.005, &p < 0.05 DKO BMM N2D6 with N1F7whole IgG versus with N1F7Fab, all by t test. N2D6 concentration was kept
constant (6.67 nM).
(B) The protective efficacy of whole IgG mAbs was compared with their F(ab0)2 fragments by MTT assay. N2D6 concentration was kept constant (6.67 nM).
(C) Percentage survival of BALB/c mice challenged with LeTx 4 hr after preinjection of PBS, mAb F(ab0)2, mAb whole IgG, or mAb mixture (1 mg whole IgG or
0.667 mg F[ab0]2 each). Representative of two independent experiments with n = 5 mice per group; **p < 0.005, log rank test.
(D) Percentage survival of WT C57BL/6 and FcRg//RIIB/mice challenged with LeTx preinjected with 1:1 mixture of N2D6 and N1F7 (1 mg each). p = 0.0005,
log rank test.
(E–G) Switching of Fc region on enhancing mAbs did not affect protective outcome when mixed with protective mAb. IgG1-enhancing mAbs, (E) N5D7 and (F)
N4H3, were class switched to IgG2a and IgG2b, respectively. MTT assay indicated no significant change of LeTx-enhancing activities for the switchedmAbs. (G)
Different classes of N5D7 and N4H3 were mixed with protective mAb, N2D6 (1 mg/ml), and the combinational protective outcome was determined byMTT assay.
Data shown are representative of three independent experiments. Means and SD of triplicates are shown from one representative experiment out of three (A and
B, E–G). See also Figure S2.
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protection.
Immunoglobulin Bivalance and FcgR Engagement Are
Required for Protection by mAb Combination
To determine the role of FcgR in the synergistic protection by
mixing mAbs, we studied the cytotoxic effect of LeTx on bone
marrow macrophages (BMMs) derived from FcRg chain/FcgRII
double knockout (DKO) (FcRg//RIIB/) mice on C57BL/6
background (Figure 4A). No protection was observed in the con-
ditions of Fab/whole IgG mixture in macrophages derived fromCell Hboth wild-type (WT) and DKO mice. In FcgR-deficient macro-
phages, the combination of mAbs still exhibited increased pro-
tection but to a lesser extent relative to the protection observed
in WT macrophages. These results revealed a role of FcgR
engagement, but the fact that depletion of FcgR did not
completely abolish the synergistic protection indicated the
presence of other underlying mechanism for this phenomenon.
We then generated F(ab0)2 of protective and enhancing
mAbs with pepsin digestion, and performed MTT assay with
various combinations. We found that the relative protective
efficacy of mAb combination was whole IgG/whole IgG > wholeost & Microbe 13, 417–428, April 17, 2013 ª2013 Elsevier Inc. 421
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Deleterious Antibodies Can Be BeneficialIgG/ F(ab0)2 > F(ab0)2/ F(ab0)2 (Figure 4B). In contrast to Fab (Fig-
ure 3D and Figure 4A), F(ab0)2 mixing resulted in synergistic pro-
tection, depicting the importance of immunoglobulin bivalence.
To confirm these observations in vivo, we performed passive im-
munization experiments in BALB/c mice using F(ab0)2 pair and to
FcRg//RIIB/ DKO mice using whole IgG pair, respectively.
The combination of protective and enhancing F(ab0)2 signifi-
cantly prolonged mouse survival compared to protective mAb
alone, while the presence of Fc region in whole IgG pair further
boosted protection against LeTx challenge (Figure 4C). The
lack of FcgR in the DKO mice reduced the protective synergy
by mAb combination (Figure 4D). Since IgG isotype can affect
neutralization efficacy (Abboud et al., 2010), we generated
switch variants of two enhancing mAbs, N4H3 and N5D7, from
IgG1 to IgG2a and IgG2b. As shown in Figures 2A–2C, N4H3
(IgG1), but not N5D7 (IgG1), augmented protection when in com-
bination with protective mAbs. When tested with the MTT assay,
the isotype switch variants, IgG2a and IgG2b, retained the same
toxin-enhancing activities as the parent IgG1 for both N4H3 and
N5D7 (Figures 4E and 4F). Furthermore, the isotype switching of
the two enhancing mAbs did not affect the overall protective
outcome when mixed with a protective mAb, indicating the
lack of Fc region preference on the synergistic protection (Fig-
ure 4G). The similar avidity of different mAb forms showed that
their binding capacity was not amajor factor of this phenomenon
(Figure S2). These results revealed that the two arms of the
immunoglobulin molecule directly determined the synergistic
protection by mixing mAb, while FcgR engagement further
increased the efficacy.
Synergistic Protection Associated with mAb-PA
Complex Formation at Optimum Molar Ratio of
Protective and Enhancing mAbs
A sufficient amount of Ab is needed for toxin neutralization,
ADCC, complement activation, and opsonization, but excessive
Ab concentrations may result in prozone-like effects that abro-
gate protection (Taborda et al., 2003). Based on the observations
that the synergistic protection against LeTx required the simulta-
neous interactions of the two mAbs on PA and that the synergy
decreased in an excess of enhancing mAbs (Figures 2A–2C and
Figures 3A–3C), we hypothesized that the augmented protection
was also dependent on the concentration of the protective mAb.
We analyzed for the ability of the combination to protect macro-
phages using the MTT assay titrating both the protective and the
enhancing mAbs (Figure 5A). The protection given by the protec-
tive mAb with minimal amount of enhancing mAb (<0.2 ng/ml)
was defined as the baseline protection. It was not surprising
that the baseline protection increasedwith the amount of protec-
tive mAb in the system. Therefore, the synergistic protections
given by mAb mixing in different molar ratios were normalized
based on the baseline protection (Figure 5B). A three-dimen-
sional presentation of the results revealed that the synergistic
protective effect observed by combining protective and
enhancing mAbs exhibited a prozone-like effect, peaking at
certain molar ratios for the two mAbs and then decreasing
when more mAb was added to the system (Figure 5C). To visu-
alize how the two mAbs interacted with PA, we conjugated the
protective mAb, enhancing mAb, and PA to Alexa Fluor-568,
-405, and -488, respectively, followed by mixing of the three pro-422 Cell Host & Microbe 13, 417–428, April 17, 2013 ª2013 Elsevierteins in molar ratios corresponding to X, Y, and Z, respectively
(Figure 5D). The protein mixture was added to J774.16 cells
and allowed to incubate for 2 hr at 4C to allow cell-based
mAb-PA interaction without macrophage ingestion (Abboud
et al., 2010). Immunofluorescence revealed the formation of
mAb-PA complexes at the molar ratio that paralleled the peak
protection of the three ratios shown (Y). As the concentration
of enhancing mAb increased, the number and size of the com-
plexes decreased. Flow cytometry was used to measure the up-
take of mAb-PA complexes by macrophages. The results
confirmed that mAb-PA complexes were most abundant in con-
dition Y and that the large size of the complexes did not affect its
binding to the cell-surface receptor and subsequent uptake by
macrophages (Figure 5E). These data indicate the tight relation-
ship between the synergistic protection by mAb mixing and
mAb-PA complex formation that occurred at optimum ratio of
the two mAbs.
A Computation Model of Antibody-Antigen Formation
Approximates Complex Molecular Mass
To determine whether this absence of protection was associated
with a lack of complex formation, we mixed mAbs in 1:1 molar
ratio in the presence of PA and analyzed complex formation by
native PAGE. We observed the formation of complexes with
high molecular weights in the mixture of PA, N2D6, and N1F7,
but not the one that involved N5D7 (Figure 6A). This result
echoed the absence of immune complex for the combination
of protective mAbs that compete for epitope on the PA molecule
(Figure S3). We then stabilized the mAb-PA interaction using a
crosslinker and performedwestern blotting probed with PA-spe-
cific IgG1 mAb 10F4 (Rivera et al., 2006). An IgG1-specific sec-
ondary Ab was used to avoid isotype crossreactivity in blot
development. The Fab of the twomAbs lacking bivalence served
as a negative control for complex formation. The results revealed
the presence of complexes with distinct, high-order molecular
weights found only in the combination of whole IgG form of the
two mAbs (Figure 6B). These molecular weights corresponded
to the possible combinations of the three proteins, and their dis-
tributions were quantified with densitometry (Figure 6C).
On the basis of these results, we constructed a simple
rule-based computational model to simulate the formation and
distribution of higher-order complexes. The rules involved a PA
molecule with two mAb binding sites and equilibrium dissocia-
tion constants (Kds) measured with SPR analysis to constrain
the binding kinetics. Remarkably, this simple model approxi-
mated the empirical distribution of mAb-PA complexes (Fig-
ure 6C). The discrepancies for some values could reflect differing
Kds for the higher-order complexes and precipitation of larger
complexes and thus effective degradation, whereas our model
implicitly assumed no correlation between degradation rate
and complex size. These findings indicate that the protective
and enhancing mAbs spontaneously formed high-order com-
plexes at optimum molar ratio.
mAb-PA Complex Formation Inhibited Oligomerization
of PA
The inactivated form of PA, PA83, is cleaved by furin on the host
cell into two fragments, PA63 and PA20, respectively (Molloy
et al., 1992), followed by the oligomerization of PA63 (PetosaInc.
Figure 5. Molar Ratio of Protective and Enhancing mAbs Determines mAb-PA Complex Formation
Protection from combining protective and enhancing mAbs peaked at optimum molar ratio of the two.
(A) The protection from N2D6 with minimal amount of N1F7 (<0.2 ng/ml) was set as baseline protection, which increased with the concentration of N2D6.
(B) To reveal the synergistic protection given solely by the addition of N1F7 to the system, the baseline protection of individual N2D6 concentration was
subtracted from the corresponding plot of mixing N2D6 and N1F7. The two-dimensional plots illustrated the results after normalization.
(C) Three-dimensional plot of net protection given by themixing of protective and enhancingmAbs with respect to protective mAb alone. The concentration of PA
and LF used in this experiment was 0.6 mg/ml each. Data shown are representative of two independent experiments (A–C).
(D) Alexa Fluor-568, -405, and -488 conjugated protective mAb, enhancing mAb, and PAmixed in molar ratio 1:0.001:1 (X), 1:1:1 (Y), or 1:20:1 (Z), and were added to
J774.16 macrophages to allow cell-based mAb-PA interaction but not phagocytosis by the cells. The cells were imaged by epifluorescence microscopy. n > 150
cells, ***p < 0.0005 and **p < 0.005, t test. Scale bar, 30 mm.
(E) J774.16 macrophage-like cells were incubated with Alexa Fluor-conjugated mAbs and PA as described in (D) followed by phagocytosis of the mAb-PA
complexes bymacrophages. The uptake wasmeasured by flow cytometry and presented as total cell-associated fluorescence. Data shown are representative of
three independent experiments. Means and SD of triplicates are shown from one representative experiment out of three (D).
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Deleterious Antibodies Can Be Beneficialet al., 1997; Kintzer et al., 2009) and the formation of a pore struc-
ture that translocates LF and edema factor (EF) into the cell
causing subsequent intoxication (Mogridge et al., 2002).
Numerous protective mAbs have been reported to inhibit
different steps of anthrax intoxication including PA binding,
cleavage, and ultimately oligomerization (Froude et al., 2011).
To determine whether the mAb-PA complex formation resulted
from the combination of protective and enhancing mAbs
affected PA oligomerization, we performed a cell-mediated
oligomer formation assay. The results revealed that the binding
of PA by either individual mAb or a combination of mAbs
influenced furin cleavage and oligomer formation differently (Fig-Cell Hure 7A). The protective mAb inhibited furin cleavage and subse-
quent oligomer formation, while the enhancing mAb did the
opposite. In contrast to the results observed with single mAb,
the combination of the protective and enhancing mAbs did not
reduce furin cleavage but still abolished oligomer formation,
suggesting another mechanism of protection. In contrast to pro-
tectivemAb alone, themixing of protection and enhancing whole
IgG mAbs resulted in mAb-PA complex formation that abolished
PA oligomerization completely (Figure 7A). The lack of inhibition
on PA oligomerization and the absence of mAb-PA complex in
the Fab mixtures confirmed the importance of mAb bivalence
in complex formation and protection against LeTx. The factost & Microbe 13, 417–428, April 17, 2013 ª2013 Elsevier Inc. 423
Figure 6. Experimental mAb-PA Complex
Formation with Discrete Molecular Weights
Concurs with Computational Model
(A) Individual mAbs or their mixture were incu-
bated with PA and subjected to native PAGE
followed by Coomassie blue staining, which aimed
to study the mAb-PA complex formation with their
natural conformations. The irrelevant mAb was
18B7 (Mukherjee et al., 1992).
(B) Individual mAbs or their mixture was incubated
with PA, and their interactions were stabilized by
crosslinker BS3. The reaction mixture was sub-
jected to SDS-PAGE followed by western blotting.
A PA-specific mAb, 10F4 (IgG1), that targeted
PA63 region of the PA molecule was used to probe
PA and its complexes with mAbs.
(C) Schematic diagram showing the components
of mAb-PA complexes with distinct molecular
weight and comparison of gel band optical density
to rule-based model. A Kolmogorov-Smirnov test
adapted for discrete distributions did not reject the
null hypothesis that the empirical and model
distributions represent samples from the same
underlying form. Error bars show sample SD. Data
shown are representative of three independent
experiments. SD of triplicates is shown from one
representative experiment out of three (C). See
also Figure S3.
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LeTx bound to PA20 (Table S1) not only revealed the mAb-PA
complex formed prior to the furin cleavage but also implied a
role of steric hindrance on toxin neutralization. We therefore
examined the combination of six enhancing mAbs with 10F4, a
protective mAb that recognizes a distant epitope on domain 4
of the PAmolecule (Rivera et al., 2006), and found no augmented
protection (Figure 7B). These results suggest that the steric
effect from multiple mAbs binding to proximal but distinct epi-
topes may play a role in toxin neutralization. Based on our exper-
imental results and their congruence with the computational
model, we propose a mechanism to account for the unexpected
protection given by the mAb combinations. The protective and
enhancing mAbs recognize distinct epitopes on the PA mole-
cules that are spatially apart to allow simultaneous binding (Fig-
ure 7C) (Potter and Lieberman, 1970). At the optimum protective
ratio between PA and the two mAbs, the bivalent property of
immunoglobulins favors the formation of mAb-PA complexes
(Figure 7C, middle two) (Potter and Lieberman, 1970; Mouquet
et al., 2010; Radjainia et al., 2010). Complex formation prior to
furin cleavage sequesters PA and prevents pore formation to
translocate LF, abrogating LeTx toxicity. The crosslinking of
FcgR further boosts the protection by increasing the uptake of
neutralized PA via phagocytosis (Aderem and Underhill, 1999).
At other molar ratios of protective and enhancing mAbs, the
mAb-PA complex can no longer form, and protection is lost (Fig-
ure 7C, top and bottom).424 Cell Host & Microbe 13, 417–428, April 17, 2013 ª2013 Elsevier Inc.DISCUSSION
The observation that the combination of
F(ab0)2 exhibited significant protective
advantage over the single mAb indicatedthat FcgR engagement was not the primary factor to determine
the synergistic protection. However, FcgR engagement still
played a significant role in contributing to protection, since
only the whole IgG mixture provided full protection against
LeTx challenge. FcgR engagement triggers signal transduction
(Anderson et al., 1990) that promotes neutralization of mAb-PA
complexes by macrophages (Abboud et al., 2010), and the dele-
tion of the g chain leads to the loss of function in FcgR-mediated
phagocytosis in macrophages (Takai et al., 1994). The combina-
tion of protective and enhancing mAbs allowed not only toxin
neutralization but also the crosslinking of FcgR, whereas the
polyvalent nature of the complexes further accelerates its
FcgR-mediated internalization and degradation inside the host
cell (Mellman and Plutner, 1984). Among all the IgG subclasses,
IgG1 is the most prevalent among the reported protective and
indifferent mAbs, while the majority of enhancing mAbs are
IgG2a (Chow and Casadevall, 2012). However, the isotype prev-
alence among the reportedmAbs does not necessarily represent
the prevalence of the most effective isotype against toxins, since
the protective efficacy of a PA-specific mAb was shown to be
IgG2a > IgG2b > IgG1 (Abboud et al., 2010). Indeed, the selec-
tion and engineering of isotype has been a focus in Ab therapeu-
tic development (Salfeld, 2007), and the choice of immunization
of adjuvants can skew the immune system to produce more IgG
of one subclass than the others (Chow and Casadevall, 2011). In
this report we observed a relatively small effect for isotype
choice on overall protection when mixing the two mAbs, which
Figure 7. mAb-PA Complex Formation Ab-
rogates PA Oligomerization
(A) PA preincubated with individual mAbs or mAb
mixture was added to J774.16 macrophages and
incubated for 45 min to allow furin cleavage,
oligomer formation, and uptake by the cells.
Whole-cell lysate was subjected to SDS-PAGE
and western blotting probed with PA-specific mAb
10F4 (IgG1) that recognized PA83, PA63, and the PA
oligomers. Data shown are representative of three
independent experiments.
(B) Protective efficacy of enhancing mAbs (red) in
the presence of protective mAbs 10F4 (green)
measured by MTT, with the concentration of 10F4
being constant as 1 mg/ml. 10F4 binds to a distant
epitope from the PA20 region of PA83, as described
by Rivera et al. (2006). Data shown are represen-
tative of two independent experiments. SD of
triplicates is shown from one representative
experiment out of two.
(C) Proposedmechanism for synergistic protection
against LeTx involving the combination of protec-
tive and enhancing mAbs. See also Table S1.
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Deleterious Antibodies Can Be Beneficialcould be explained by the observation that the bivalence was the
dominant requirement for the effect rather than the type of Fc
engagement.
Anthrax toxin was used in our study to illustrate the ability of
individually characterized enhancing mAbs to benefit the host
in combination with other mAbs, but we anticipate that the un-
derlying mechanism of the protection can be applied to other
microbes. Despite the fact that this study used a specific
monomeric antigen, we propose that the findings here may
be extrapolated to other monomeric toxins or even viruses
with repetitive epitopes. Crosslinking of virions by mAbs leads
to aggregation and neutralization, whereas this process can
be reversed by papain digestion, suggesting the critical role
of mAb bivalence in forming immune complexes (Thomas
et al., 1985; Colonno et al., 1989). Antibody-dependent
enhancement of virus infection has been shown to be medi-
ated by the Fc region of the immunoglobulin (Takada and Ka-
waoka, 2003), so the combination of F(ab0)2 may reduce
enhancement while potentially providing synergistic protection
by forming complexes with the virion. Our results showed that
the protective efficacy of a mAb established using the immu-
noglobulin alone cannot be extrapolated to conditions in which
other Abs are present, although meeting these conditions may
not be sufficient for certain Ab pairs to mediate protection. For
example, the mixing of protective and nonprotective Abs can
abrogate protective efficacy against polysaccharide antigens
that possess less-defined molecular weight and structure
(Nussbaum et al., 1996, De Jesus et al., 2010; Cordero
et al., 2011).
Emergent properties cannot be explained by the individual
components alone, and usually reflect an outcome that is
greater than the sum of the parts with a certain form of noveltyCell Host & Microbe 13, 417–(Ablowitz, 1939). Microbial virulence, net-
works of biological signaling pathways,
and even evolution of life are examples
of emergent properties in nature (Bhallaand Iyengar, 1999; Corning, 2002, Casadevall et al., 2011). Our
findings thatmAbs characterized as disease enhancing on single
Ab assays can benefit the host in combination with other Abs
provide an example of emergent properties in AMI. These results
demonstrate combinatorial complexity in Ab interactions,
challenging the view that one can assign biological activity to a
single immunoglobulin molecule that retains its meaning in the
context of other types of such molecules, and suggest the
need for a new conceptual framework to understand AMI. At a
practical level, it is possible that many Abs categorized as
indifferent or enhancing when studied alone have the potential
for protective functions in combination with other Abs, and
many potentially useful Abs are likely being discarded in the
search for anti-infective and anticancer therapeutics. In the
past decade the systems biology approach has become a prom-
inent means to study emergent properties in biological sci-
ences—it can be used to model gene expression of pathogenic
microbes (Kanjilal et al., 2010) and predict immunogenicity of
vaccines in humans (Querec et al., 2009). On the basis of
emerging high-throughput technology and the systems biology
platform, combination testing of mAbs could reveal new proper-
ties of previously neglected mAbs and transform the direction
and approach in therapeutics development against various in-
fectious diseases and cancers.
EXPERIMENTAL PROCEDURES
Hybridomas and Monoclonal Antibodies to PA
BALB/c mice 8–10 weeks of age were immunized with the GalXM-PA conju-
gate generated from our lab (Chow and Casadevall, 2011). Hybridomas
were generated by fusing splenocytes to NSO or Bcl2 myeloma fusion partner
(de StGroth and Scheidegger, 1980). The specificity and isotype of mAbs were
tested with ELISA.428, April 17, 2013 ª2013 Elsevier Inc. 425
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The sequencing of the heavy chain and light chain of the antibody variable
region was performed as described previously with modification (Rivera
et al., 2006). Briefly, total RNA of hybridoma cells was isolated, and genomic
DNA was removed. cDNA was synthesized, and mAb variable domains were
generated by PCR with universal 50 end (sense) variable region and specific
30 end (antisense) constant region primers. The amplified PCR products
were sequenced at the Sequencing Core Facility at AECOM. The sequences
were then compared to the mouse immunoglobulin database using IgBLAST
to determine gene usage.
Cell Viability Assay
Cell viability of macrophages was analyzed by MTT (3-[4,5-dimethylthiazol-2-
yl] 2,5-diphenyltetrazolium bromide) assay as described (Abboud et al., 2010).
Briefly, J774.16 cells and BMM were treated with LeTx (0.3 mg/ml PA and
0.3 mg/ml LF unless specified) in the presence or absence of a specific
mAb(s) for 4 hr and 72 hr, respectively. In the experiments of mixing mAbs,
the mAb with constant concentration was at 1 mg/ml and the other mAb being
titrated from 30 mg/ml, unless specified. The percentage viability was calcu-
lated as (ODexperimental – ODmin viability)/(ODmax viability – ODmin viability) *100,
whereas ODmax viability and ODmin viability were obtained from cells treated
with media only and overdose of LeTx, respectively.
Cytotoxicity Assay
Cell-mediated cytotoxicity was measured by CytoTox 96 nonradioactive
cytotoxicity assay (Promega). Cells treated with lysis solution were used as
maximum LDH release control, whereas cells with media only were used as
baseline LDH release control.
Animal Experiments
Eight- to ten-week-old female BALB/c mice were preinjected with PBS,
individual mAb (1 mg), or mAb mixture (1 mg each) intraperitoneally 4 hr prior
to LeTx challenge. LeTx (35 mg PA and 35 mg LF per mouse) was injected intra-
venously. Equal amount of enhancing mAb was used, in order to fulfill the
condition of 1:1 molar ratio between the mAb pairs. For the survival studies
that compared the protective efficacy of F(ab0)2 and whole IgG in BALB/c
mice, and that involvedWT C57/BL6 and FcRg//RIIB/mouse experiment,
LeTx (40 mg PA and 40 mg LF per mouse) was used. All experiments were done
in compliance with federal laws and institutional guidelines and have been
approved by the Albert Einstein College of Medicine.
Inhibition ELISA
Costar plates were coated with PA (2 mg/ml), followed by the addition of a pro-
tective mAb and an enhancing mAb. The concentration of the first antibody
was kept constant at 2 mg/ml, while the other was titrated from 60 or
180 mg/ml, and vice versa. An alkaline phosphatase-conjugated goat anti-
mouse antibody with isotype specific to the first antibody was used to detect
mAb-mAb competition. The absorbance was measured at 405 nm.
Fluorescence Labeling of PA and mAbs and Immunofluorescence
Imaging
Protective mAb N2D6, enhancing mAb N1F7, and PA were conjugated to
Alexa Fluor-568, -405, and -488 (Molecular Probes, Invitrogen), respectively,
following the manufacturer’s instructions. They were mixed in molar ratios
1:0.001:1 (condition X), 1:1:1 (Y), or 1:20:1 (Z) (concentrations of Alexa Fluor-
conjugated protective mAb, enhancing mAb, and PA were 0.5 mg/ml, 5 3
104/0.5/10 mg/ml, and 0.5 mg/ml, respectively) and preincubated with
J774.16 macrophage-like cells at 4C for 2 hr to allow interactions and recep-
tor binding (Abboud et al., 2010). Cells were washed, fixed with 4% parafor-
maldehyde, and imaged by epifluorescence microscopy.
Measurement of PA Uptake by Flow Cytometry
The procedures were similar to that of fluorescence labeling, except that after
2 hr incubation at 4C the cells were washed to remove unbound complex/
mAbs/PA, followed by incubation at 37C for 30 min to allow phagocytosis
of the antibody-antigen complex. The internalization of complex takes place
within 30min (Abboud et al., 2010), so all bound complexes should be uptaken426 Cell Host & Microbe 13, 417–428, April 17, 2013 ª2013 Elsevierby the macrophage before the cells are resuspended and subjected to flow
cytometry.
Native Gel Electrophoresis
PA and mAb(s) were mixed in 1:1 (or 1:1:1) molar ratios (5.55 mM) and
incubated at 37C for 2 hr. The mixtures were subjected to native PAGE using
NuPAGE Novex 3%–8% Tris-Acetate Gel (Invitrogen) followed by Coomassie
staining.
Crosslinking Experiment and Western Blotting
Combinations of PA, N2D6whole IgG, N2D6Fab, N1F7whole IgG, andN1F7Fab of the
same concentration (5.55 mM), at molar ratio 1:1:1 for N2D6:N1F7:PA were
incubated at 37C for 2 hr. A water-soluble crosslinker, bis[sulfosuccinimidyl]
suberate (BS3) (Thermo Scientific), was used to induce crosslinking between
PA and mAb(s) following the manufacturer’s instructions. The reaction was
performed at room temperature for 30 min and terminated by the addition of
Tris-HCl. The reaction mixture was subjected to SDS-PAGE, with no boiling
of samples, using NuPAGE Novex 3%–8% Tris-Acetate Gel followed by west-
ern blotting. A PA-specific mAb, 10F4 (IgG1), and Alexa Fluor680-conjugated
goat anti-mouse IgG1 antibody were used as the primary and secondary anti-
bodies, respectively (Rivera et al., 2006). The signal was detected by Odyssey
Infrared Imager (LI-COR) at 700 nm and analyzed with Image Studio software
(LI-COR) and ImageJ.
Cell-Mediated PA Oligomer Formation Assay
Cell-mediated oligomer formation of PA63 was studied as described previously
with modification (Rivera et al., 2006). Briefly, PA83 was preincubated in
variation with N2D6whole IgG, N2D6Fab, N1F7whole IgG, and N1F7Fab of the
same concentration (36 mM) at 37C for 2 hr. The mixture was added to
J774.16 macrophage-like cells and incubated for 45 min to allow furin cleav-
age, oligomer formation, and uptake by the cells. The culture was washed
with PBS and lysed. The reaction mixture was subjected to nonreducing
SDS-PAGE and western blotting as described above. The signal was detected
by Odyssey Infrared Imager at 700 nm.
Rule-Based Modeling
The BioNetGen language (BNGL) was used to implement a rule-based model
of complex formation due to antibody-antigen binding (Faeder et al., 2009;
Chylek et al., 2011). Simulations were performed using the Gillespie stochastic
simulation algorithm (Gillespie, 1977). We used a version of the KS test that is,
in contrast to themost commonly used forms that apply only to continuous dis-
tributions, applicable to discrete distributions (Gleser, 1985).
Statistics
The statistical significance for all in vitro assays was determined by the Stu-
dent’s t test. Survival rate of the animal experiments was analyzed with the
log-rank test. All the statistical analyses were performed using Prism software
(GraphPad Software, Inc.).
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